Synopsis: Aurobindo Pharma Limited has announced a share buyback of up to 54.23 lakh fully paid-up equity shares at a price of Rs.1,475 per share, aggregating to a maximum of Rs.800 crore, through the tender offer route in accordance with SEBI Buyback Regulations, 2018. The buyback will open on April 23, 2026, and close on April 29, 2026, with settlement expected to be completed by May 7, 2026.
Aurobindo Pharma Limited has announced a Rs.800 crore share buyback, under which the company plans to repurchase up to 54.23 lakh equity shares at a price of Rs.1,475 per share through the tender offer route. The buyback window is scheduled to open on April 23, 2026, and close on April 29, 2026, with April 17 set as the record date to determine eligible shareholders.
Aurobindo Pharma has a total market capitalization of Rs. 81,120.56 crore, according to data on the NSE. The stock was listed on the exchanges on July 19, 2000. The company has already dispatched the Letter of Offer to eligible shareholders as of the record date, April 17, 2026. The buyback price of Rs.1,475 per share typically represents a premium over the prevailing market price, which could provide an attractive exit opportunity for shareholders in the short term. At the same time, such corporate actions often support the stock price by reducing the number of outstanding shares and improving earnings per share (EPS).
Overall, Aurobindo Pharma Rs. 800 crore buyback reflects a capital allocation strategy aimed at rewarding shareholders and improving financial ratios like earnings per share. However, its true impact will depend on how effectively the company continues to execute its growth strategy, navigate regulatory challenges, and maintain profitability in a competitive global pharmaceutical landscape.
Aurobindo Pharma shares were trading at Rs. 1398.5 apiece on the National Stock Exchange; the stock has gained around 1.57% over the last five sessions, while it has surged about 9.37% in the 30 days. Over a six-month period, the stock has given a high return of 27.24%, whereas on a year-on-year basis it has gained nearly 17.75%, reflecting a strong overall performance. The stock’s 52-week high was Rs. 1,401.10 and 52-week low was Rs. 1016.10
Aurobindo Pharma is one of India’s leading pharmaceutical companies with a strong global presence, particularly in generic medicines and active pharmaceutical ingredients (APIs). Over the years, the company has expanded its footprint across key international markets, including the United States and Europe, while strengthening its product portfolio across therapeutic segments.
Buyback History
This is Aurobindo Pharma’s first share buyback in nearly two years. Back in August 2024, the company had announced the repurchase of 51.36 lakh equity shares at a price of Rs.1,460 apiece. The drugmaker had spent Rs. 750 crore for this buyback, which was also carried out via the tender offer route.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
